NVO peer analysis
Novo Nordisk (NVO) against its competitors: price, today's move, 1-year return and market value side by side.
NVO and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ABBV AbbVie | $288.70 | -2.10% | 26.51% | $521.11B |
| AMGN Amgen | $466.58 | 0.12% | 59.79% | $251.94B |
| AZN AstraZeneca | $186.41 | -0.13% | 13.20% | $289.48B |
| GSK GSK | $49.04 | -0.95% | 4.47% | $99.19B |
| JNJ Johnson & Johnson | $268.64 | -1.67% | 42.10% | $657.68B |
| LLY Eli Lilly | $1,404.38 | -0.93% | 66.30% | $1.26T |
| MRK Merck | $148.63 | -0.60% | 72.26% | $368.89B |
| PFE Pfizer | $30.64 | 0.39% | 26.14% | $173.95B |
| SNY Sanofi | $45.24 | 2.03% | -11.19% | $106.24B |
| NVO Novo Nordisk | $40.66 | 1.65% | -18.75% | $176.43B |
- NVO's peers: ABBV (AbbVie), AMGN (Amgen), AZN (AstraZeneca), GSK (GSK), JNJ (Johnson & Johnson), LLY (Eli Lilly), MRK (Merck), PFE (Pfizer).
Updated 2026-11-02 17:54 UTC